In a groundbreaking move, Be The Match BioTherapies®, a pioneering organization that offers solutions for companies venturing into the development and commercialization of cell and gene therapies, has announced a strategic partnership with Cryoport, a global leader in providing innovative products and services to the rapidly evolving cell & gene therapy sector.
A Partnership for the Future of Medicine
This collaboration is set to enhance the capabilities of IntegriCell™, a comprehensive solution for bioprocessing, cryopreservation, and distribution tailored for the global cell therapy market. With state-of-the-art cryopreservation facilities located in both the U.S. and Europe, IntegriCell™ is strategically positioned to bolster both decentralized and centralized manufacturing models. This will, in turn, expedite patient access to groundbreaking new therapies.
The partnership aims to offer unparalleled bioprocessing and cryopreservation support across the U.S. and Europe. By integrating Be The Match BioTherapies’ unmatched expertise in donor identification and high-quality starting material collection with Cryoport’s industry-leading cryopreservation, bioprocessing, and global logistics capabilities, the IntegriCell™ solution is designed to deliver optimized cellular starting material.
This will be achieved by ensuring cell processing within 24 hours post-collection, using standardized protocols executed by seasoned professionals. The ultimate goal is to offer cell and gene therapy researchers, developers, and manufacturers consistent starting materials that are cryopreserved to enhance manufacturing efficiency, leading to faster and more cost-effective market introductions of new cell and gene therapies.
Mark Sawicki, President and CEO at Cryoport Systems Inc., expressed his enthusiasm about the partnership, stating that cell and gene therapy developers have faced challenges in delivering consistent starting materials that meet their rigorous standards. He believes that this collaboration with Be The Match BioTherapies will pave the way for best-in-class solutions for the cell and gene therapy industry.
Echoing these sentiments, Chris McClain, Senior Vice President Sales and Business Development at Be The Match BioTherapies, emphasized the potential of IntegriCell to revolutionize the cell therapy ecosystem, leading to more consistent manufacturing yields and improved clinical outcomes.
About Be The Match BioTherapies
Be The Match BioTherapies stands out as the sole cell and gene therapy solutions provider that offers customizable services to support the entire cell therapy supply chain. The organization is backed by the extensive experience of the National Marrow Donor Program®/Be The Match® and a research collaboration with the CIBMTR® (Center for International Blood and Marrow Transplant Research®).
Their mission is to accelerate patient access to life-saving cell and gene therapies by providing top-tier cellular source material from the Be The Match Registry®, the world’s most diverse registry with over 7 million potential blood stem cell donors.
About Cryoport, Inc
Cryoport, Inc. is a global frontrunner in offering innovative products and services to the burgeoning Cell & Gene Therapy industry, marking the dawn of a new era in life sciences. With a presence in 48 strategic locations across 17 countries, Cryoport’s global platform delivers vital bio-logistics, bio-storage, bio-processing, cryopreservation, and cryogenic systems to life sciences markets worldwide.
For more details, visit Be The Match BioTherapies and Cryoport.